The Untapped Potential of Office-Based Buprenorphine Treatment

March 2, 2016

Opioid abuse and dependence are reaching epidemic proportions in the United States, resulting in a staggering number of overdose deaths and economic costs that exceed $56 billion annually. Medication-assisted therapies, such as buprenorphine (Suboxone) and methadone, represent the most efficacious treatments for opioid dependence. Office-based buprenorphine treatment is especially well positioned to provide a rapid […]

Read the full article →

BUPRENORPHINE AND NALOXONE (Buprenorphine Hydrochloride And Naloxone Hydrochloride Dihydrate) Tablet [Actavis Pharma, Inc.]

March 2, 2016

Updated Date: Feb 11, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Science Be Damned: Americans Prefer Broken Method Of Heroin Treatment, Survey Finds

March 2, 2016

In developed countries around the globe, the standard of care for opiate addiction is what’s known as “medically assisted treatment.” Under a doctor’s supervision, people with addictive disorders are prescribed medications like methadone, buprenorphine and Suboxone, which remove the cravings associated with opiate addiction. In the U.S., however, by far the most common form of […]

Read the full article →

Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions

March 2, 2016

This article reviews the current evidence for medication-assisted treatment of opioid use disorder and also presents clinical practice imperatives for preventing opioid overdose and the transmission of infectious disease. The evidence strongly supports the use of agonist therapies to reduce opioid use and to retain patients in treatment, with methadone maintenance remaining the gold standard […]

Read the full article →

Buprenorphine-Naloxone treatment of prescription opioid abuse: does past performance predict future results?

March 2, 2016

Authors: Langleben DD Abstract Misuse of prescription opioids is a national public health problem: In the United States, according to the 2012 National Survey on Drug Use and Health, 4.5 million, or 1.7%, of persons aged 12 or older reported current nonmedical use of pain relievers, and 335,000 reported currently using heroin. This is an […]

Read the full article →

BUPRENORPHINE HCL AND NALOXONE HCL (Buprenorphine And Naloxone) Tablet [Amneal Pharmaceuticals Of New York, LLC]

March 2, 2016

Updated Date: Mar 10, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone: HIV Prevention Trials Network 058

March 2, 2016

Conclusions: Participants receiving BUP/NX 3 times weekly were more likely to reduce opioid injection while on active treatment. Both treatment strategies were considered safe and associated with reductions in injection-related risk behavior. These data support the use of thrice-weekly BUP/NX as a way to reduce exposure to HIV risk. Continued access to BUP/NX may be […]

Read the full article →

Non-controlled and over-the-counter drugs of abuse

March 2, 2016

  2.5 out of 5 stars Abuse of Medications That Theoretically Are Without Abuse Potential. Reeves RR et al. South Med J 2015 Mar;108:151-157. Abstract This review of noncontrolled prescription and over-the-counter drugs that can be and have been abused for non-medical or recreational purposes is rather sketchy and anecdotal (as the authors admit,) but nevertheless […]

Read the full article →

Zubsolv (Buprenorphine and Naloxone Sublingual Tablets) – updated on RxList

March 2, 2016

(Source: RxList – New and Updated Drug Monographs) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.

March 2, 2016

Authors: Sullivan JG, Webster L Abstract PURPOSE: The purpose of this study was to provide a preliminary assessment of the safety, tolerability, symptom control, and acceptability of buprenorphine-naloxone buccal film (BBN) for the maintenance treatment of opioid dependence in patients converted from buprenorphine-naloxone sublingual tablet or film (SLBN), as well as to determine the conversion […]

Read the full article →

← Previous Entries

Next Entries →